(Q45422025)

14 December 2017

Fatal hepatitis B virus reactivation in a chronic myeloid leukemia patient during imatinib mesylate treatment (English)

1 reference

14 December 2017

chronic myeloid leukemia

0 references

1 reference

1 reference

1 reference

1 reference

1 reference

Ikeda K

1

1 reference

14 December 2017

Shiga Y

2

1 reference

14 December 2017

Takahashi A

3

1 reference

14 December 2017

Kai T

4

1 reference

14 December 2017

Kimura H

5

1 reference

14 December 2017

Takeyama K

6

1 reference

14 December 2017

Noji H

7

1 reference

14 December 2017

Ogawa K

8

1 reference

14 December 2017

Nakamura A

9

1 reference

14 December 2017

Ohira H

10

1 reference

14 December 2017

Sato Y

11

1 reference

14 December 2017

Maruyama Y

12

1 reference

14 December 2017

1 January 2006

1 reference

14 December 2017

1 reference

14 December 2017

47

1 reference

14 December 2017

1

1 reference

14 December 2017

155-157

1 reference

Effects of a selective inhibitor of the Abl tyrosine kinase on the growth of Bcr-Abl positive cells

14 December 2017

1 reference

https://api.crossref.org/works/10.1080%2F14639230500236818

Hematologic and cytogenetic responses to imatinib mesylate in chronic myelogenous leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14639230500236818

Imatinib induces durable hematologic and cytogenetic responses in patients with accelerated phase chronic myeloid leukemia: results of a phase 2 study

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14639230500236818

Imatinib mesylate-induced hepato-toxicity in chronic myeloid leukemia demonstrated focal necrosis resembling acute viral hepatitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14639230500236818

Histological features of acute hepatitis after imatinib mesylate treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14639230500236818

Comprehensive analysis of risk factors associating with Hepatitis B virus (HBV) reactivation in cancer patients undergoing cytotoxic chemotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14639230500236818

High hepatitis B virus (HBV) DNA viral load as the most important risk factor for HBV reactivation in patients positive for HBV surface antigen undergoing autologous hematopoietic cell transplantation

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14639230500236818

Severe hepatitis and complete molecular response caused by imatinib mesylate: possible association of its serum concentration with clinical outcomes

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14639230500236818

A small molecule-kinase interaction map for clinical kinase inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14639230500236818

Imatinib mesylate inhibits T-cell proliferation in vitro and delayed-type hypersensitivity in vivo

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14639230500236818

Imatinib inhibits the activation and proliferation of normal T lymphocytes in vitro

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14639230500236818

Efficacy of imatinib mesylate (STI571) treatment for a patient with rheumatoid arthritis developing chronic myelogenous leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14639230500236818

Lamivudine prophylaxis for prevention of chemotherapy-induced hepatitis B virus reactivation in hepatitis B virus carriers with malignancies

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14639230500236818

Factors associated with viral breakthrough in lamivudine monoprophylaxis of hepatitis B virus recurrence after liver transplantation

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14639230500236818

10.1080/14639230500236818

21 January 2018

Identifiers

DOI

1 reference

14 December 2017

1 reference